Superior Complete Response Rate (CR) and Progression-Free Survival (PFS) with Bortezomib-Thalidomide-Dexamethasone (VTD) Versus Thalidomide-Dexamethasone (TD) As Consolidation Therapy After Autologous Stem-Cell Transplantation (ASCT) in Multiple Myeloma (MM)Michèle Cavo, Michele Baccarani, Giuseppe Rossi et al.|Blood|2011Cited by 7
Thromboprophylaxis for Newly Diagnosed Multiplemyeloma Patients Treated With Lenalidomide-Basedregimens: A Randomized Phase Iii Study of Aspirinvs EnoxaparinAlessandra Larocca, Antonio Palumbo, Federica Cavallo et al.|Unknown|2011Cited by 0
CO-OCCURRENCE OF JAK2/CALR-POSITIVE MYELOPROLIFERATIVE DISORDER AND BCR-ABL-POSITIVE CHRONIC MYELOGENOUS LEUKAEMIA TREATED WITH COMBINATION OF TYROSINE KINASE INHIBITORS AND RUXOLITINIB.Katia Paciaroni, Tommaso Caravita di Toritto, Nicoletta Villivà et al.|Mediterranean Journal of Hematology and Infectious Diseases|2025Cited by 0